BMYCongressional Stock Trades
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
Congressional stock trades in Bristol-Myers Squibb Co. (BMY) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
17
Politicians Trading
10
Last Traded
Jun 16, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Alan ArmstrongR | Jul 21, 2026 | Mar 27, 2026 | Buy | $1,001 - $15,000 | +5.42% |
| Ro KhannaD | Jul 6, 2026 | Jun 16, 2026 | Sell | $1,001 - $15,000 | +10.35% |
| Mike KellyR | Jun 11, 2026 | May 7, 2026 | Sell | $15,001 - $50,000 | +9.71% |
| Ro KhannaD | Jun 9, 2026 | May 15, 2026 | Buy | $1,001 - $15,000 | +8.26% |
| Julie JohnsonD | Jan 15, 2026 | Dec 18, 2025 | Sell | $1,001 - $15,000 | +15.71% |
| Julia LetlowR | Jan 13, 2026 | Apr 28, 2025 | Sell | $1,001 - $15,000 | +27.34% |
| Gilbert Ray Cisneros, Jr.D | Jan 12, 2026 | Dec 19, 2025 | Buy | $1,001 - $15,000 | +13.88% |
| Gilbert Ray Cisneros, Jr.D | Dec 15, 2025 | Nov 12, 2025 | Buy | $1,001 - $15,000 | +25.73% |
| Julie JohnsonD | Dec 11, 2025 | Nov 13, 2025 | Sell | $1,001 - $15,000 | +26.90% |
| Gilbert Ray Cisneros, Jr.D | Nov 18, 2025 | Oct 9, 2025 | Sell | $1,001 - $15,000 | +38.12% |
| Julie JohnsonD | Sep 11, 2025 | Aug 14, 2025 | Sell | $1,001 - $15,000 | +29.07% |
| Virginia FoxxR | Jul 3, 2025 | Jun 24, 2025 | Sell | $1,001 - $15,000 | +31.21% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 - $50,000 | +28.08% |
| Tommy TubervilleR | May 15, 2025 | Apr 15, 2025 | Sell | $1,001 - $15,000 | +23.42% |
| Julie JohnsonD | May 14, 2025 | Apr 1, 2025 | Sell | $1,001 - $15,000 | +3.63% |
| Greg LandsmanD | Apr 8, 2025 | Mar 27, 2025 | Sell | $1,001 - $15,000 | +4.77% |
| Julie JohnsonD | Feb 12, 2025 | Jan 15, 2025 | Buy | $1,001 - $15,000 | +10.37% |
Price History
About Bristol-Myers Squibb Co.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
10 members of Congress have disclosed 17 trades in Bristol-Myers Squibb Co. (BMY). Most active: Julie Johnson (5), Gilbert Ray Cisneros, Jr. (3), Ro Khanna (2).
Across all disclosures, members of Congress reported 5 purchases and 12 sales of Bristol-Myers Squibb Co. (BMY). The most recent trade was on Jun 16, 2026.
Ro Khanna disclosed buying Bristol-Myers Squibb Co. (BMY) on May 15, 2026, valued at $1,001 - $15,000.
Ro Khanna disclosed selling Bristol-Myers Squibb Co. (BMY) on Jun 16, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.